electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025
electroCore (Nasdaq: ECOR) will report third quarter results for the period ended September 30, 2025 after market close on Wednesday, November 5, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
electroCore (Nasdaq: ECOR) will report third quarter results for the period ended September 30, 2025 after market close on Wednesday, November 5, 2025. Management will host a results webinar on November 5, 2025 at 4:30 PM EST to review the financial results and answer questions.
Investors can join via dial-in (646) 931-3860, Webinar ID 822 9598 1338, passcode 454695, or register using the provided registration link to participate and ask questions.
Details
News Market Reaction – ECOR
On Oct 23, the day this news came out, ECOR closed 1.45% above the previous close.
Data tracked by StockTitan Argus for the Oct 23 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKAWAY, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the third quarter ended September 30, 2025, after the close of the market on Wednesday, November 5, 2025.
Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below:
Wednesday, November 5, 4:30 PM EST
Dial-In: (646) 931-3860
Webinar ID: 822 9598 1338
Passcode: 454695
Registration Link: Click here to participate and ask questions on the call.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.